News

SkylineDx and Biocartis Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™

ROTTERDAM (the Netherlands), SAN DIEGO (US), April 22, 2021: SkylineDx and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announce the signing of a new partnership agreement which targets...

SkylineDx further expands its footprint in the United States

ROTTERDAM (the Netherlands), SAN DIEGO (US), March 23, 2021: SkylineDx received the first Merlin Assay clinical test requests and therefore reported initial gross sales ahead of the commercial launch at the World Congress...

SkylineDx, Oncode Institute and Utrecht Holdings sign license agreement for innovative algorithm RAINFOREST

ROTTERDAM (The Netherlands) and SAN DIEGO (US), February 23, 2021: today, SkylineDx announces to have signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm...

SkylineDx achieves new milestone with ISO 13485:2016 certification

ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 18, 2021: today, SkylineDx announced that it received the esteemed ISO 13485:2016 Quality Management System certificate from notified body BSI Netherlands, after their successful audit...

Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence

ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 15, 2021: today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer)...

SkylineDx inks collaboration agreement with Imperial College London and UCSD on diagnostic test Kawasaki Disease

ROTTERDAM (the Netherlands), SAN DIEGO (US), LONDON (UK), September 10, 2020: SkylineDx, announces a collaboration agreement with Professor Michael Levin’s group at Imperial College London and Professor Jane Burns’ group at University of...

How the Dutch resume elective surgery in melanoma after COVID delays

ROTTERDAM (the Netherlands) and SAN DIEGO (US), August 26, 2020: SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to...

SkylineDx signs 10th collaboration agreement under Falcon Melanoma R&D Program

ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 23, 2020: last week, SkylineDx signed the 10th collaboration agreement with an academic partner for research under the extensive Falcon R&D Program to further validate...

Prognostic model reveals high-risk melanoma patients that need a clinical trial

ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 14, 2020: SkylineDx announces the publication of two ASCO abstracts describing a biomarker that identifies a subgroup of skin cancer (cutaneous melanoma) patients that could...

Private health insurance reimburses MMprofiler with SKY92 for patients United Kingdom

ROTTERDAM (the Netherlands) and SAN DIEGO (US), May 12, 2020: Everything Genetic Ltd has partnered with a leading private health insurance company in the UK to design an access strategy for patients with...

SkylineDx launches melanoma test in United States to support cancer care

ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 22, 2020: SkylineDx announced today that the Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from...

Skin cancer test reduces need for surgery

ROTTERDAM (the Netherlands) and SAN DIEGO (US), April 15, 2020: SkylineDx in collaboration with the Mayo Clinic published yesterday its first study describing a diagnostic test that could reduce up to 42% of...

SkylineDx and BioInvent to collaborate on patient stratification to maximize impact of treatment with BI-1206

ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 24, 2020: SkylineDx today announces an agreement with BioInvent International AB (OMXS: BINV) to characterize the gene expression and immunological signatures in tumors of patients...

National Research Cancer Institute UK confirms benefit molecular profiling in multiple myeloma

ROTTERDAM (the Netherlands) and SAN DIEGO (US), March 17, 2020: multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches,...

First German hospital to implement MMprofiler (SKY92) in real-world setting

ROTTERDAM (the Netherlands) and SAN DIEGO (US), February 4, 2020: SkylineDx is excited to announce the scientific collaboration with the Multiple Myeloma (blood cancer) specialized department of the Wuerzburg University Medical Center II...

SkylineDx confirms positive results first independent validation skin cancer test

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 30, 2019: SkylineDx announced, during the European Society for Medical Oncology congress (Barcelona, EU), that it successfully validated the performance of their skin cancer (melanoma) diagnostic...

SkylineDx and Mayo Clinic collaborate on implementing skin cancer test in clinical practice

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 24, 2019: SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester (MN, US) the launch of a pilot study it will...

Combination of multiple myeloma diagnostics finds lenalidomide benefit

ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 12, 2019: fast-progressing multiple myeloma (blood cancer) patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when...